KIDS

ORTHOPEDIATRICS CORP

Healthcare | Small Cap

-$0.35

EPS Forecast

$59.04

Revenue Forecast

The company already released most recent quarter's earnings. We will publish our AI's next quarter's forecast around 2026-07-20

OrthoPediatrics (KIDS) Expands 2026 Revenue Outlook as Q1 Revenue Rises 13%

In this first-quarter print from the pediatric orthopedic specialist, the focus is on revenue growth, adjusted EBITDA progress, and an upshift in the full-year revenue forecast. Notably, the press release does not include a reported EPS figure, leaving investors to parse margins and top-line momentum for any potential earnings surprise versus EPS consensus.

Headline metrics: revenue, geography, and margins

  • Total revenue: $59.4 million, up 13% year over year from $52.4 million.
  • U.S. revenue: $45.3 million, up 11% YoY (76% of total).
  • International revenue: $14.1 million, up 22% YoY (about 24% of total).
  • Adjusted EBITDA: $2.2 million in Q1 2026, versus a ($0.4) million result in Q1 2025.
  • Free cash flow usage: reduced by 40% versus the prior year period.
  • Outlook: 2026 revenue guidance raised to $263.0–$267.0 million, representing roughly 11%–13% growth year over year.

Product mix and customer impact drive the narrative

The company attributes the revenue mix to strength across its Trauma & Deformity and Scoliosis franchises. In the quarter, Trauma & Deformity revenue reached $43.0 million, up about 14% from the prior year period, buoyed by products like Pega, Ex-Fix, and OPSB. Scoliosis revenue totaled $15.4 million, rising around 13% YoY, driven by increased sales of Response and VerteGlide systems and the introduction of 7D technology.

Sports Medicine/Other revenue remained modest at $0.9 million, roughly flat with the prior year. The company highlighted OPSB (the platform it’s scaling) as a key growth vector, supported by new product introductions and clinic expansion that broadens access to its portfolio.

Management rhetoric and strategic read-through

David Bailey, OrthoPediatrics’ President and CEO, framed the results as a strong start to 2026, noting momentum across international markets and OPSB-driven growth. The commentary pointed to a multi-year product cycle intended to lift average selling prices (ASPs), expand margins, and improve returns, all while deepening hospital partnerships and accelerating product launches.

From a strategic standpoint, the emphasis on OPSB growth and international expansion suggests the company is trying to credibly balance near-term profitability with a longer-term ramp in adoption and share in pediatric trauma and deformity care. The shift in revenue guidance signals confidence in executing the plan, though the absence of an accompanying EPS figure makes it harder to judge whether the margin trajectory is keeping pace with top-line strength.

Outlook implications for OrthoPediatrics and peers

The raised 2026 revenue forecast positions OrthoPediatrics as one of the more confidently guiding names in pediatric orthopedics, especially with a stated aim of growth in the 11%–13% range. For investors, the key questions revolve around whether adjusted EBITDA will sustain its recent trajectory as revenue scales and how durable the OPSB-led growth is amid hospital procurement cycles and competition in endoscopy- and hardware-related segments.

In a broader sector context, the combination of double-digit international growth and steady U.S. growth could set a benchmark for peers pursuing a similar OPSB-centric strategy or those relying on a multi-product portfolio to propel top-line expansion. If OrthoPediatrics can translate its product cycle into sustained margin expansion, the earnings narrative may increasingly hinge on cadence—how quickly clinics adopt new devices and how efficiently the business can scale service and parts ecosystems.

Risks, questions, and the EPS cross-check

With no EPS figure disclosed in the release, investors will look to the upcoming quarterly filings to reconcile top-line growth with per-share profitability. The absence of an explicit EPS consensus leaves room for near-term “earnings surprise” ambiguity until more granular earnings data arrives. The key risks center on margin progression, the sustainability of OPSB expansion, and any variable cost pressures as the company invests in product development and clinic expansion.

From a sector perspective, peers with similar product cycles will be watching whether OrthoPediatrics’ revenue trajectory translates into durable margin gains and how management allocates capital between R&D, sales, and international expansion. The market will also weigh how sensitive the growth story is to reimbursement dynamics, adoption rates, and competition in pediatric orthopedic devices.

Bottom line

OrthoPediatrics delivered a solid Q1, with revenue up 13% and adjusted EBITDA turning positive as the company leans into OPSB-driven growth and a multi-year product cycle. A higher revenue forecast for 2026 underscores management’s optimism about market adoption and mix improvements, even as the absence of a reported EPS figure keeps the per-share profitability question top-of-mind for some investors. If the trajectory persists, KIDS could emerge as a leading indicator for growth-oriented, asset-light pediatric orthopedics platforms, potentially shaping how peers price and pace expansions in the years ahead.